Search PubMed⌕ Search

Biomedical subjects

Pamela Bean

Publications and source records attributed to Pamela Bean.

29 records · Page 2Linked to original sources
PubMed2002

Streamlining microarray technology in a prototype core laboratory.

The overall scheme of a microarray experiment is summarized in Figure 3. The real benefit of using microarrays in research is gaining knowledge from the abundant data provided from the series of related microarray experiments. The core laboratory has produced three cDNA arrays, a mouse 15K array, a human 13K array, and a human apoptosis array with 350 plus apoptotic elements. Recently, the 15K array is being used in building a database for gene expression in several areas of the mouse brain and for studying transgenic and knockout mice. The apoptosis array has been used by cancer researchers to further elucidate changes and interactions between genes leading to cell death and cancer. The UCHSC Gene Expression Array Core is supported by the National Institute on Aging and the National Cancer Institute (Bethesda, MD) to serve all academic users and has a special interest in providing a solid technological base for genomic researchers interested in alcohol and cancer research.

Animals↗
PubMedDate not supplied

Detection of alcohol misuse using a routine test panel: the early detection of alcohol consumption (EDAC) test.

AIMS: This study describes the derivation and validation of the early detection of alcohol consumption (EDAC) test, which uses linear discriminant function (LDF) analysis for the identification of alcohol misuse. This form of LDF aims to predict a categorical dependent variable (alcohol misuse) on the basis of several independent, predictor variables (routine laboratory tests). METHODS: EDAC was developed to classify individuals as heavy or light drinkers using a database of 1599 subjects recruited from 25 sites in the USA. The predictor variables for the LDF were 36 routine chemistry and haematology analytes. RESULTS: The EDAC model produced 80.7% sensitivity and 84.4% specificity, with an overall correct classification rate of 82.5%. Using a stepwise method, 20 of the 36 routine tests used in the LDF were selected as the optimal predictor variables. The top three variables with the highest contribution in the stepwise EDAC model were: bilirubin ratio (direct to total), aspartate aminotransferase and albumin. CONCLUSIONS: This study shows that LDF analysis in conjunction with new, user-friendly computer packages is a practical and cost-effective laboratory tool for detecting excessive drinking using blood constituents ordered routinely in a variety of clinical settings. Diagnostic performance can be adjusted to achieve higher specificity rates.

Adolescent↗
PubMedDate not supplied

HIV: the road ahead.

Explore the source record for details and available documents.

Anti-HIV Agents↗
PubMedDate not supplied

Role of HIV phenotypic assays in the management of HIV infection.

Contemporary phenotypic assays such as the PhenoSense HIV assay are more straightforward to interpret than genotyping results because they do not require the expert interpretation of complex mutation patterns. The drug susceptibility data provides information for the clinician to select a treatment regimen effective against the predominant viral population circulating in the patient's blood. Compared to traditional phenotypic assays, the PhenoSense HIV assay uses a virus vector and a luciferase reporter gene to provide a quick and sensitive measure of viral replication. The main use of phenotypic assays at present is to identify those antiretroviral drugs that still retain activity against the patient's virus. Phenotypic assays are useful to provide guidance after treatment failure and to select a proper combination of drugs prior to initiation of therapy. They are also useful to detect transmission of resistance virus and to monitor HIV patients during early viral rebound. In essence, phenotypic testing provides information to target antiretroviral therapy against the predominant HIV variant in the patient for a prolonged suppression of viral replication, decreased mortality, and lower health-care costs.

Anti-HIV Agents↗